Related Experiment Videos
High-dose Mydocalm therapy in certain myogenous headaches
Therapia Hungarica (English Edition)
|January 1, 1989
Summary
Intermittent Mydocalm therapy effectively treated myogenous cephalalgia in 113 patients. Tolperisone relieved muscle spasms and hypertonicity, improving function and controlling headaches within a week.
Area of Science:
- Neurology
- Pharmacology
- Musculoskeletal Medicine
Background:
- Myogenous cephalalgia is often associated with muscle spasm and hypertonicity.
- Effective treatment options for chronic muscle-related headaches are continually sought.
Purpose of the Study:
- To evaluate the efficacy of oral Mydocalm (tolperisone) in treating myogenous cephalalgia.
- To assess the impact of tolperisone on muscle rigidity and functional improvement in patients with headaches.
Main Methods:
- A study involving 113 patients diagnosed with myogenous cephalalgia.
- Intermittent oral therapy with Mydocalm (tolperisone) at a daily dose of 150 mg.
Main Results:
- Significant relief from spasm, hypertonicity, and rigidity in occipital, cervical, and shoulder muscles was observed.
- Functional improvement and successful control of myogenous cephalalgias were achieved within 3-7 days of treatment initiation.
Conclusions:
- Oral Mydocalm (tolperisone) demonstrates effectiveness in managing symptoms of myogenous cephalalgia.
- Tolperisone offers a viable therapeutic option for reducing muscle-related pain and improving quality of life in affected individuals.